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Objectives This paper sought to evaluate whether high sensitivity troponin (hs-cTnT) can immediately exclude acute myocar-
dial infarction (AMI) at a novel ‘rule out’ cut-off.
Background Subgroup analysis of recent evidence suggests that undetectable hs-cTnT may exclude AMI at presentation.
Methods In a cohort study, we prospectively enrolled patients with chest pain, evaluating them with standard troponin T
and testing for hs-cTnT (Roche Diagnostics, Basel, Switzerland) at presentation. The primary outcome was a di-
agnosis of AMI. We also followed up patients for adverse events within 6 months. After subsequent clinical im-
plementation of hs-cTnT, we again evaluated whether initially undetectable hs-cTnT ruled out a subsequent rise.
Results Of 703 patients in the cohort study, 130 (18.5%) had AMI, none of whom initially had undetectable hs-cTnT (sen-
sitivity: 100.0%, 95% confidence interval [CI]: 95.1% to 100.0%, negative predictive value: 100.0%, 95% CI:
98.1% to 100.0%). This strategy would rule out AMI in 27.7% of patients, 2 (1.0%) of whom died or had AMI
within 6 months (1 periprocedural AMI, 1 noncardiac death). We evaluated this approach in an additional 915
patients in clinical practice. Only 1 patient (0.6%) with initially undetectable hs-cTnT had subsequent elevation (to 17
ng/l), giving a sensitivity of 99.8% (95% CI: 99.1% to 100.0%) and a negative predictive value of 99.4% (95% CI:
96.6% to 100.0%).
Conclusions Undetectable hs-cTnT at presentation has very high negative predictive value, which may be considered to rule
out AMI, identifying patients at low risk of adverse events. Pending further validation, this strategy may reduce
the need for serial testing and empirical treatment, enabling earlier reassurance for patients and fewer unnec-
essary evaluations and hospital admissions. (J Am Coll Cardiol 2011;58:1332–9) © 2011 by the American
College of Cardiology FoundationDespite extensive research and evolving diagnostic technol-
ogy, patients with symptoms possibly resulting from an
acute coronary syndrome usually undergo investigation for
at least 6 hours (and often longer) before acute myocardial
infarction (AMI) can be excluded confidently (1–3). Thus
in many centers, including ours, most patients (74% to 88%)
are admitted to hospital, making up more than one-quarter
of acute medical admissions. Only a minority (approxi-
mately 25%) ultimately are diagnosed with an acute coro-
nary syndrome, and many fewer are diagnosed with AMI
(4–6). A strategy that would enable AMI or acute coronary
syndrome to be excluded at the time of presentation would
be extremely helpful and likely would substantially reduce
unnecessary hospital admissions. Clinical judgment alone is
clearly insufficient to fulfill that goal, because up to 6% of
patients with chest pain who are discharged from the
emergency department (ED) have been reported to have
had unrecognized AMI. Missed AMI in this setting has
significant prognostic implications (7,8).
Recently, Reichlin et al. (9) and Keller et al. (10) reported
that using more sensitive troponin assays can increase
diagnostic accuracy by ruling in AMI for a greater propor-
tion of patients at the time of initial presentation. However,
using the conventional cutoff (the 99th percentile of a
healthy reference population), the sensitivity of these novel
assays was approximately 90%, meaning that serial testing
remains necessary before AMI can be ruled out. Among the
assays evaluated by Reichlin et al. (11) was the Elecsys
high-sensitivity cardiac troponin T (hs-cTnT) assay (RocheDiagnostics). We noted that, using the lower detection limit
of this assay as a cutoff, AMI seemed to be ruled out
(sensitivity: 100%). If so, such a strategy would have enabled
the exclusion of AMI in those with such low values (9.9% of
the population) at the time of admission (12). If these
findings could be validated, hs-cTnT could be used to
reduce some of the unnecessary hospital admissions. Such
an approach would lower resource utilization, would im-
prove quality of care for patients, and would lead to earlier
ED discharges. Accordingly, we set out to investigate
whether AMI can be safely ruled out in patients with
undetectable levels of hs-cTnT at the time of presentation
to the ED.
See page 1340
Methods
There were 2 parts to our investigation: an initial prospec-
tive cohort study to validate the findings of Reichlin et al.
(12) in the context of a research environment and a
prospective clinical audit to validate our findings in clinical
practice. The prospective cohort study was approved by the
local research ethics committee. The U.K. National Re-
search Ethics Service confirmed that the clinical audit did
not require ethical approval.
Prospective cohort study. The cohort study was a sub-
study of the Early Vascular Markers of Acute Coronary
Syndromes project, which aims to develop a novel algorithm
for the early exclusion of acute coronary syndromes in the
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recruited patients who sought
treatment at the ED with chest
pain at Manchester Royal Infir-
mary, a university-affiliated teach-
ing hospital with an annual ED
census of approximately 145,000.
We included patients who were
older than 25 years and had chest
pain within the previous 24 h
that the initial treating physician
suspected may be cardiac in na-
ture. Patients were excluded if they had renal failure
requiring dialysis, trauma with suspected myocardial contu-
sion, or another medical condition mandating hospital
admission or if they did not consent to and provide a blood
sample for use by the research team.
Blood was drawn at the time of ED presentation and
immediately centrifuged. Serum was separated and frozen at
–200°C for up to 48 h and at –700°C thereafter. Following
an amendment to the initial protocol (also approved by the
local research ethics committee), previously unthawed sam-
ples were tested for hs-cTnT (99th percentile: 14 ng/l,
coefficient of variation 10% at 9 ng/l) and fourth-
generation cardiac troponin T (cTnT) (99th percentile:
10 ng/l, coefficient of variation 10% at 30 ng/l) by
laboratory personnel who were blinded to patient outcomes
(11). Testing was completed in August 2009.
All patients underwent testing with the fourth-generation
cTnT assay at least 12 h after the onset of the most
significant symptoms. Patients then were followed up after
48 h, 30 days, and 6 months. At follow-up, the National
Health Service Strategic Tracing Service database (a na-
tional database with mortality statistics updated on at least
a weekly basis) initially was checked for mortality data. The
cause of death was retrieved for all deceased patients.
Electronic hospital records then were reviewed for every
patient, including details of all subsequent ED attendances,
hospital admissions, out-patient clinic appointments, and all
investigations requested or undertaken. All living patients
then were contacted by telephone. In the event that a
patient could not be contacted after multiple attempts, their
general practitioner was contacted. In the event that a
patient was hospitalized at another hospital during the
follow-up period, copies of relevant records were obtained.
Outcomes. The primary outcome was a diagnosis of AMI.
This final diagnosis was adjudicated by 2 independent
investigators (R.B. and S.C.) who had all clinical, labora-
tory, and imaging data available for review, but who were
blinded to hs-cTnT levels. In accordance with the universal
definition of AMI, patients were considered to fulfill the
criteria for AMI if they had a rise or fall of cTnT, or both,
above the 99th percentile (10 ng/l) in the appropriate
clinical context (18). For patients with modest elevations of
cTnT (0.1 ng/ml) at baseline, an absolute difference of at
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CI  confidence interval
cTnT  cardiac troponin T
ED  emergency
department
hs-cTnT  high-sensitivity
cardiac troponin Tleast 20 ng/l on serial sampling was considered to represent ma significant rise, fall, or both (19) based on the analytical
performance of the cTnT assay. To ensure that we did not
ignore significant cTnT rises that were not classified as
AMI, we also undertook a sensitivity analysis to investigate
the ability of admission hs-cTnT level to predict any
subsequent cTnT elevation of more than 10 ng/l (the 99th
percentile) with the standard assay, regardless of the cause.
Secondary outcomes included death (all-cause) and incident
AMI (i.e., not including the index event but including any
evolving AMI that was identified more than 12 hours after
initial symptom onset) within 6 months.
Evaluation of hs-cTnT use in clinical practice. In Octo-
ber 2010, we introduced the Roche hs-cTnT assay into
clinical practice at our institution. Clinical personnel were
asked to draw blood for hs-cTnT testing at the time of
presentation and (regardless of the initial level) at least 12 h
after symptom onset. After 3 months, we identified all
patients who had undergone at least 2 hs-cTnT tests during
the same hospital admission since the introduction of the
assay. We then calculated the sensitivity, specificity, and
positive and negative predictive values of the initial hs-
cTnT level for predicting any subsequent hs-cTnT elevation
(14 ng/l) on serial testing.
Statistical analysis. Because hs-cTnT levels showed poor
conformity to the normal distribution (p  0.05, 1-sample
olmogorov-Smirnov test), nonparametric techniques were
sed to analyze the data. Data were summarized using the
edian and interquartile range. We used the Mann-
hitney U test to compare hs-cTnT levels between groups
ith and without each outcome.
We analyzed the overall diagnostic performance of hs-
TnT by calculating the area under the receiver-operating
haracteristic curve. The sensitivity and negative predictive
alue of both tests were calculated at the lower limit of
etection of the assay (i.e., the predefined cutoff of 3 ng/l for
s-cTnT) and at the 99th percentile cutoff (14 ng/l for
s-cTnT; 10 ng/l for cTnT). Sensitivities and specificities
ere compared using McNemar’s test for paired propor-
ions. Statistical analyses were undertaken using SPSS
oftware version 16.0 (SPSS, Inc., Chicago, Illinois), except
or calculation of sensitivity, specificity, positive predictive
alue, negative predictive value, and McNemar’s test, which
ere undertaken using MedCalc software version 11.3.6.0
MedCalc Software, Mariakerke, Belgium).
esults
ohort study. In total, 804 patients consented to inclusion
n the cohort study between January 2006 and February
007, of whom 703 were eligible for inclusion in this
nalysis (Fig. 1). Baseline characteristics of included patients
re shown in Table 1. The patients for whom no serum
ample was available (n  93) were more likely to have a
istory of hypertension, but were otherwise not significantly
ifferent to included patients. Follow-up was complete to 6
onths for all 703 patients. The median time from symp-
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(18.5%) patients had an adjudicated diagnosis of AMI.
After 6 months, 30 patients (4.3%) had died or had AMI.
There were 15 deaths (2.1%) and 21 AMIs (3.0%); 6
patients with AMI died.
For establishing a diagnosis of AMI, the area under the
receiver-operating characteristic curve of the initial hs-
cTnT level was 0.94 (95% confidence interval [CI]: 0.91 to
0.96), which was significantly greater than that for cTnT
(0.86, 95% CI: 0.82 to 0.91, p  0.0001) (Fig. 2). No
patients with an hs-cTnT value of 3 ng/l at the time of
presentation had AMI, giving a sensitivity of 100.0% (95%
CI: 97.2% to 100.0%) and a negative predictive value
100.0% (95% CI: 98.1% to 100.0%). The sensitivity for
excluding AMI with these criteria remained 100.0% (95%
CI: 95.1% to 100.0%) even among the 324 (46.1%) patients
who had blood drawn within 3 h of symptom onset (Table
2). If this cutoff were used purely to enable early exclusion of
AMI in some ED patients, 27.7% of patients could have
AMI ruled out at the point of ED presentation. Specificity
Figure 1 STARD Flow Diagram
Flow diagram demonstrating inclusions and exclusions according to the Standards
AMI  acute myocardial infarction; hs-cTnT  high-sensitivity cardiac troponin T.when using the 3-ng/l cutoff was low (34.0%, 95% CI: t30.2% to 38.1%). Using the conventional 99th percentile
cutoff value (14 ng/l), sensitivity for excluding AMI fell, but
remained significantly higher than for the initial sample
cTnT (85.4% vs 75.2%, difference: 10.2%, p  0.0002).
During the 6-month follow-up period, 2 (1.0%) patients
with an hs-cTnT value of 3 ng/l experienced death or
AMI. One of these patients, who initially gave a classical
history of crescendo angina, continued to be asymptomatic
and underwent inpatient percutaneous coronary interven-
tion within 30 days, which was complicated by periproce-
dural AMI. The other patient died of noncardiac causes
(esophageal carcinoma) within 6 months of presentation.
Using this strategy, patients with hs-cTnT of 3 ng/l at
resentation would have had AMI ruled out a median of 9.6 h
arlier (interquartile range: 6.0 to 10.8 h). Given that this is a
ubstantial percentage of our population, this would have saved
cumulative total of 1,547 inpatient hours. It also would have
voided some empirical treatment. In this situation, 101
51.8%) of the patients with hs-cTnT of 3 ng/l received
reatment with clopidogrel in the ED and 84 (43.1%) received
porting for Diagnostic Accuracy Studies (STARD).of Rereatment with low molecular weight heparin.
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more than 10 ng/l regardless of the cause, the sensitivity of
hs-cTnT at the time of presentation using the 3 ng/l
cutoff value remained 100.0% (95% CI: 97.8% to 100.0%).
Prospective audit of hs-cTnT in clinical practice. We
implemented the hs-cTnT assay in clinical practice on
October 6, 2010, and collated the results on January 6, 2011.
During that time, a total of 915 patients underwent at least
2 hs-cTnT tests during the same admission. The mean age
of these patients was 65.9 years and 528 (57.7%) were male.
The diagnostic performance of the initial hs-cTnT level for
predicting a subsequent rise of hs-cTnT of more than 14
ng/l on serial testing is shown in Table 3. Only 1 patient
with initial hs-cTnT of 3 ng/l subsequently had an
elevation (to 17 ng/l). Thus, by ruling out AMI in patients
with initial hs-cTnT of3 ng/l, we would have avoided the
need for serial hs-cTnT testing in 17.5% of patients, at a
cost of missing 0.17% of subsequent hs-cTnT elevations.
The only patient in whom subsequent hs-cTnT elevation
would have been missed sought treatment within 1 h of
symptom onset and was admitted to the coronary care unit.
The patient was diagnosed with vasovagal syncope but died
unexpectedly a week after discharge, with the registered
cause of death being ischemic heart disease.
Discussion
This research breaks new ground concerning the ability to
Baseline Characteristics of Included PatientsTable 1 Baseline Characteristics of Included Patients
Variable Total (N  703)
Age, yrs 58.6 14.3
Men 430 (61.2)
Previous angina 221 (31.4)
Previous myocardial infarction 167 (23.8)
Hypertension 343 (48.8)
Hyperlipidemia 339 (48.2)
Diabetes mellitus 125 (17.8)
Smoking 216 (30.7)
Family history of ischemic heart disease 338 (48.1)
Previous coronary intervention 140 (19.9)
Peripheral vascular disease 13 (1.8)
Cerebrovascular disease 71 (10.1)
Chronic renal impairment 7 (1.0)
Current aspirin use 300 (42.7)
Current clopidogrel use 84 (11.9)
Current statin use 311 (44.2)
Current ACE inhibitor use 165 (23.5)
Current beta-blocker use 170 (24.2)
Time from symptom onset, h
0–3 324 (46.1)
3–6 167 (23.8)
6–12 151 (21.5)
12 61 (8.7)
Values are mean  SD or %.
ACE  angiotensin converting enzyme; AMI  acute myocardial infarction.use novel, high-sensitivity techniques to facilitate the earlyexclusion of AMI. Validating the findings presented by
Reichiln et al. (12) in a separate investigation, our data from
a total of more than 1600 patients demonstrate that, at the
lower detection limit, this novel fifth-generation hs-cTnT
assay has very high sensitivity at the time of presentation
(100.0% [95% CI: 97.2% to 100.0%] and 99.8% [95% CI:
99.1% to 100.0%] in the cohort study and audit, respectively).
We also demonstrated that these patients have a low subse-
quent 6-month event rate. If this strategy were relied on to
exclude AMI immediately in practice, our data suggest that as
many as 27.7% of patients could be reassured immediately.
Assuming that as many as 15 million patients seek
treatment each year with chest pain at EDs (20), the
strategy we report could avoid prolonged evaluation, includ-
ing serial troponin testing, in approximately 4 million
patients. This would obviate the need for serial troponin
testing, would avoid unnecessary empirical treatment with
its consequent risks, would enable clinicians to consider
alternative diagnoses at an early stage, and would reduce
unnecessary hospital admissions, unburdening EDs and
easing overcrowding. Our study did not evaluate the cost-
effectiveness of this strategy. There is clearly potential for
substantial cost savings, and there is evidently a very low risk
of missed AMI. However, a formal assessment of cost
savings against the potential costs of missed AMI would be
a worthwhile goal for future studies.
The novel high-sensitivity troponin assays are yet to be
AMI (n  130) Did Not Have AMI (n  573) p Value
63.2 13.6 57.6 14.2 0.001
88 (67.7) 342 (59.7) 0.091
30 (23.1) 191 (33.3) 0.023
30 (23.1) 137 (23.9) 0.841
64 (49.2) 279 (48.7) 0.912
55 (42.3) 284 (49.6) 0.135
26 (20.0) 99 (17.3) 0.464
57 (43.8) 159 (27.7) 0.001
55 (42.3) 283 (49.4) 0.145
22 (16.9) 118 (20.6) 0.344
2 (1.5) 11 (1.9) 0.771
12 (9.2) 59 (10.3) 0.716
2 (1.5) 5 (0.9) 0.490
43 (33.1) 257 (44.9) 0.014
13 (10.0) 71 (12.4) 0.448
49 (37.7) 262 (45.7) 0.096
27 (20.8) 138 (24.1) 0.421
23 (17.7) 147 (25.7) 0.056
79 (60.8) 245 (42.8) —
26 (20.0) 141 (24.6) —
22 (16.9) 129 (22.5) —
3 (2.3) 58 (10.1) —Hadapproved for clinical use in the United States, although the
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mented in parts of Europe. There also have been reports of
many other highly sensitive assays (21–24). If this approach is
applicable to all such novel assays, it would have a profound
impact on the ability to evaluate patients rapidly in the ED.
It is unlikely that any paradigm that is proposed will be
perfect. Indeed, it should be recognized that the lower
Figure 2 ROC Curve Analysis
Receiver-operating characteristic (ROC) curves demonstrating diagnostic accu-
racy of admission hs-cTnT and cardiac troponin T (cTnT) for AMI. AUC  area
under the receiver-operating characteristic curve; CI  confidence interval;
other abbreviations as in Figure 1.
Sensitivity and Specificity of hs-cTnT for AMI at Selected Cutoffs, STable 2 Sensitivity and Specificity of hs-cTnT for AMI at Select
Time From
Symptom Onset (h) Assay and Cutoff Sensitivity (95% CI)
All patients hs-cTnT, 3 ng/l* 100.0 (97.2–100.0)
hs-cTnT, 14 ng/l† 85.4 (78.1–91.0)
cTnT, 10 ng/l† 75.2 (66.8–82.4)
3 hs-cTnT, 3 ng/l 100.0 (95.1–100.0)
hs-cTnT, 14 ng/l 79.7 (68.8–88.2)
cTnT, 10 ng/l 66.2 (54.3–76.8)
3 hs-cTnT, 3 ng/l 100.0 (93.6–100.0)
hs-cTnT, 14 ng/l 92.9 (82.7–98.0)
cTnT, 10 ng/l 87.3 (75.5–94.7)
6 hs-cTnT, 3 ng/l 100.0 (97.3–100.0)
hs-cTnT, 14 ng/l 82.9 (74.3–89.5)
cTnT, 10 ng/l 71.2 (61.5–79.6)
6 hs-cTnT, 3 ng/l 100.0 (94.2–100.0)
hs-cTnT, 14 ng/l 96.0 (79.7–99.9)
cTnT, 10 ng/l 92.0 (74.0–99.0)*Rule out cutoff set at the lower limit of detection of the assay. †Cutoff set at the 99th percentile of a re
CI  confidence interval; cTnT  cardiac troponin T; hs-cTnT  high-sensitivity cardiac troponin T; NPVbounds of the 95% CIs for sensitivity extend to 97.2% in the
cohort study and 99.1% in the audit. Research suggests that
physicians will accept this level of risk (25), which may be
less risk than in current practice (7,8). However, it is
important to remember the potential medical and medico-
legal implications of missed diagnoses of AMI. The risk-
adjusted mortality rate for patients who are discharged with
unrecognized AMI is almost twice as high as for hospital-
ized patients (8). Further, missed myocardial infarction is a
leading cause for malpractice claims in the United States
(26). The potential costs of 1 missed diagnosis therefore
must be weighed against the costs of hospital admission for
further testing, which may lead some to feel uncomfortable
with implementing this strategy without further evidence.
We currently are undertaking a further prospective valida-
tion study to address such concerns. In addition, it is
important to acknowledge that troponins are markers of
myocardial necrosis. Although our strategy may exclude
AMI, some patients with unstable angina without AMI
may not be identified. Thus, there will always be a role for
careful evaluation of each individual patient.
Others may be concerned that a rapid rule-out protocol
will miss AMI in those who seek treatment early and in
patients with evolving AMI. The low incidence of adverse
events in our study confirms that the risk of missing
evolving AMI is small. In our evaluations, the only patient
with undetectable initial hs-cTnT who had a subsequent
rise sought treatment within 1 h of symptom onset. It
therefore may be a prudent precaution to repeat testing after
1 to 2 h in patients seeking treatment so early, although this
strategy warrants formal prospective evaluation.
These data, as with all research, inevitably will lead to
further important questions. Because high-sensitivity assays
will detect many more subtle elevations indicative of cardiac
injury, the specificity of hs-cTnT for AMI as compared
fied by Time From Symptom Onsetutoffs, Stratified by Ti e From Symptom Onset
Specificity (95% CI) PPV (95% CI) NPV (95% CI)
34.0 (30.2–38.1) 25.6 (21.9–29.6) 100.0 (98.1–100.0)
82.4 (79.0–85.4) 52.4 (45.4–59.2) 96.1 (94.0–97.7)
94.6 (92.4–96.3) 75.8 (67.4–82.9) 94.4 (92.2–96.2)
63.8 (57.2–70.1) 47.7 (39.7–55.9) 100.0 (97.5–100.0)
83.0 (77.5–87.7) 60.8 (50.4–70.6) 92.5 (88.0–95.8)
94.6 (90.8–97.2) 80.3 (68.2–89.4) 89.5 (84.8–93.1)
32.7 (27.8–37.9) 19.2 (14.9–24.3) 100.0 (96.8–100.0)
82.0 (77.5–85.8) 45.2 (35.9–54.8) 98.6 (96.5–99.6)
94.5 (91.6–96.7) 71.6 (59.3–82.0) 97.9 (95.8–99.2)
34.5 (29.7–39.4) 29.3 (24.7–34.3) 100.0 (97.3–100.0)
82.9 (78.8–86.5) 56.9 (48.6–64.8) 94.7 (91.7–96.8)
95.3 (92.7–97.2) 80.4 (70.9–88.0) 92.5 (89.4–94.9)
33.2 (26.5–40.4) 16.7 (11.1–23.6) 100.0 (94.2–100.0)
81.3 (74.9–86.6) 40.7 (28.1–54.3) 99.4 (96.4–100.0)
93.0 (88.3–96.2) 63.4 (46.2–79.2) 98.9 (95.9–99.9)tratied Cference population.
 negative predictive value; PPV  positive predictive value.
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Some therefore may voice concern that using the lower
detection limit as a cutoff will compromise specificity
further. However, we should be clear that this is merely a
rule-out cutoff value and should not be used to define
abnormality. Thus, patients should not be labeled as abnor-
mal at values of less than the 99th percentile of a reference
population. For patients with detectable levels of hs-cTnT,
AMI cannot be ruled out at the time of presentation; they
should undergo further investigation, including further tro-
ponin testing. Many of these patients still can have AMI
ruled out after subsequent hs-cTnT testing, but some will
have AMI. This proposed use of hs-cTnT relies on a good
understanding of the concepts ‘SpIn’ (‘Specificity’ rules ‘In’)
and ‘SnOut’ (‘Sensitivity’ rules ‘Out’) (27). It bears similar-
ities to our current use of D-dimer for exclusion of venous
thromboembolism (28) and the rule-in and rule-out cutoffs
suggested for natriuretic peptides in the evaluation of suspected
acute decompensated heart failure (29).
It may be possible at some time to develop a strategy to
evaluate a larger percentage of patients more rapidly than at
6 to 12 h after symptom onset, but our data do not provide
insight into that issue. We have not investigated the added
value of serial hs-cTnT estimation in this study. This is the
goal of our future studies, to address 2 further important
questions: (1) At what level of hs-cTnT can we consider
AMI to be ruled in, provided there is a demonstrable rise or
fall, or both, in concentrations? (2) For how long must
patients undergo serial hs-cTnT estimations to differentiate
robustly all patients with AMI from those without AMI?
Study limitations. For our initial analysis, we tested for
hs-cTnT in samples that had been stored at –70°C (without
freeze-thaw cycles) for approximately 2.5 years. There are
currently no data about the stability of the assay under these
conditions, which raises the possibility that levels in the
cohort study were influenced by sample instability. How-
ever, troponin T as measured with this assay is known to be
stable for 12 months after storage at –20°C (30), suggesting
(but not confirming) that instability is unlikely to be an issue
in this study. Further, the findings of our prospective
evaluation (where testing was contemporaneous) suggest
that sample instability is unlikely to have influenced our
results significantly.
Some may be concerned that the analytical imprecision of
the assay at this cutoff may lead to inaccurate results. Our
findings clearly demonstrate that this does not lead to
significant false negative results. However, it is possible that
Evaluation of hs-cTnT Use in Clinical Practice: Dof Initial hs-cTnT Level for Pred cting Any SubseTable 3 Evaluation f hs-cT T Use in Clinicaof Initial hs-cTnT Level for Predictin
hs-cTnT Cutoff Sensitivity (95% CI) Specific
3 ng/l 99.8 (99.1–100.0) 49.5
14 ng/l 98.4 (97.0–99.3) 87.9
Abbreviations as in Table 2.there were some false positive results. This may be why wecould exclude only 30% of patients at the time of
presentation. By achieving greater analytical sensitivity and
precision through future assay development, perhaps this
number could be increased still further.
Conclusions
Our findings validate previous work and demonstrate that,
at the lower detection limit, hs-cTnT has very high sensi-
tivity for AMI at the time of presentation, with the lower
bounds of the 95% confidence intervals being 97.2% and
99.1% in our 2 cohorts. This strategy could enable clinicians
immediately to exclude AMI in up to 27.7% of patients.
These patients are at low risk of significant adverse events
within 6 months. This strategy could be used to obviate the
need for serial troponin testing and empirical treatment and
to reduce unnecessary hospital admissions. Further valida-
tion is warranted to yield tighter confidence intervals and to
establish firmly the earliest time point at which AMI may be
excluded safely using this novel high-sensitivity assay.
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